Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab roll-over study for patients benefiting after prior oncology trials
2023-507337-22-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 32
01
Overview
Phase 3, open-label, single-arm trial of durvalumab in transitional cell carcinoma (TCC), non-urothelial carcinoma of the urinary tract, non-small cell lung cancer (NSCLC) and 1 more, sponsored by AstraZeneca. Primary endpoint: Serious adverse events. Planned start Jun 2022; status: authorised.
02
Drugs
durvalumab
03
Conditions
transitional cell carcinoma (TCC)non-urothelial carcinoma of the urinary tractnon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2023-507337-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507337-22-00.